Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

KETACANCER: Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCC

To see complete record on, please visit this link

Id: NCT04459234

Organisation Name: Centre Leon Berard

Overal Status: Recruiting

Start Date: February 2, 2021

Last Update: October 4, 2022

Lead Sponsor: Centre Leon Berard

Brief Summary: The primary objective of this study is to describe the administration practices of the antalgic Ketamine in French CLCC (Centre de Lutte Contre le Cancer) in terms of indication (neuropathic sequelae pains, morphine additional effect or morphine withdrawal, intensity, localisation…) and administration protocol (route, posology, duration, administration sequence, premedication).

The secondary objectives are to evaluate in the context of cancer, the analgesic efficacy, the tolerance profile (biological and clinical toxicities) and the quality of life, including anxiety and depression.

In addition, the described parameters will be evaluated as safety and efficacy predictive factors of the Ketamine in oncology.

  • Cancer
  • Chronic Pain
  • Neuropathic Pain
  • Opioid Use

Total execution time in seconds: 0.3047890663147